Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
Public ClinicalTrials.gov record NCT02756572. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Feasibility Study of "Early" Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasms
Study identification
- NCT ID
- NCT02756572
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- University of Washington
- Other
- Enrollment
- 30 participants
Conditions and interventions
Conditions
- Blasts 10 Percent or More of Bone Marrow Nucleated Cells
- Chronic Myelomonocytic Leukemia-2
- High Grade Malignant Neoplasm
- Myelodysplastic Syndrome
- Myelodysplastic Syndrome With Excess Blasts-2
- Myeloid Neoplasm
- Previously Treated Myelodysplastic Syndrome
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
- Cladribine Drug
- Cyclosporine Drug
- Cytarabine Drug
- Filgrastim Biological
- Fludarabine Phosphate Drug
- Allogeneic Hematopoietic Stem Cell Transplantation Procedure
- Laboratory Biomarker Analysis Other
- Melphalan Drug
- Mitoxantrone Hydrochloride Drug
- Mycophenolate Mofetil Drug
- Questionnaire Administration Other
- Sirolimus Drug
- Total-Body Irradiation Radiation
- Melphalan Hydrochloride Drug
Drug · Biological · Procedure + 2 more
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 21, 2016
- Primary completion
- Feb 29, 2020
- Completion
- Jun 30, 2020
- Last update posted
- Nov 7, 2021
2016 – 2020
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02756572, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 7, 2021 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02756572 live on ClinicalTrials.gov.